What is the ticker symbol for Nurix Therapeutics?

Nurix Therapeutics trades under the ticker NRIX on NASDAQ.

What sector does Nurix Therapeutics operate in?

Nurix Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze NRIX in a portfolio?

PortView shows NRIX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Nurix Therapeutics (NRIX) Stock Analysis

NASDAQHealthcareBiotechnology

$25.51-2.04%

1-year price historyRange $8.24 – $27.79

52-week range$25.51

$8.20$28.23

What Nurix Therapeutics does

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Key metrics

Market cap

$2.65B

P/E (TTM)

-7.39

EPS (TTM)

$-3.45

Beta

1.79

Dividend yield

0.00%

Revenue / share

$0.33

50-day avg

$24.55

200-day avg

$18.71

52-week high

$28.23

52-week low

$8.20

CEO

Arthur T. Sands

ETFs linked to NRIX

Broad-market and Healthcare sector ETFs an investor holding Nurix Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how NRIX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze NRIX in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Nurix Therapeutics?: Nurix Therapeutics trades under the ticker NRIX on NASDAQ.
Which exchange is NRIX listed on?: NRIX is listed on NASDAQ.
What sector does Nurix Therapeutics operate in?: Nurix Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze NRIX in a portfolio?: PortView shows NRIX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.